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Introduction
Osteochondral tissue is hard to regenerate after injuries or 
degenerative diseases. So far, clinical treatments such as 
chondral shaving, abrasion arthroplasty, subchondral drill-
ing, microfracturing, mosaicplasty, and prosthetic joint 
replacement have been available for the patients suffering 
from osteochondral pain.1,2 However, these treatments are 
still challenging due to their own disadvantages, such as 
unsuitable donor tissue availability, donor site morbidity, 
implant loss, and limited durability of prosthetics.3–5
Alternatively, tissue engineering approaches of using 
various types of bioavailable scaffolds, proper cell sources, 
and/or bioactive signaling molecules have recently 
emerged to substitute and replace the patient-painful treat-
ments. Among the tissue engineering components, scaf-
folds play significant roles in providing three-dimensional 
(3D) environments for cells to populate on and to differen-
tiate into proper lineages.6,7 These tissue-engineering scaf-
folds can be readily supplied and easily prepared without 
the need to consider immune/disease problem, costs, and 
availability. Above all, the design and properties of scaf-
folds should be importantly considered in order to induce 
satisfactory cell functions and to maximize therapeutic 
roles of bioactive molecules which are involved in the 
osteochondral repair processes.
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Abstract
Interest in osteochondral repair has been increasing with the growing number of sports-related injuries, accident traumas, 
and congenital diseases and disorders. Although therapeutic interventions are entering an advanced stage, current 
surgical procedures are still in their infancy. Unlike other tissues, the osteochondral zone shows a high level of gradient 
and interfacial tissue organization between bone and cartilage, and thus has unique characteristics related to the ability 
to resist mechanical compression and restoration. Among the possible therapies, tissue engineering of osteochondral 
tissues has shown considerable promise where multiple approaches of utilizing cells, scaffolds, and signaling molecules 
have been pursued. This review focuses particularly on the importance of scaffold design and its role in the success of 
osteochondral tissue engineering. Biphasic and gradient composition with proper pore configurations are the basic design 
consideration for scaffolds. Surface modification is an essential technique to improve the scaffold function associated with 
cell regulation or delivery of signaling molecules. The use of functional scaffolds with a controllable delivery strategy of 
multiple signaling molecules is also considered a promising therapeutic approach. In this review, we updated the recent 
advances in scaffolding approaches for osteochondral tissue engineering.
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In this topical review, we update strategies of osteo-
chondral repair and regeneration, with particular emphasis 
on the recent designs and technologies in the development 
of scaffolds. For this, we begin with a brief explanation of 
the osteochondral tissue hierarchy and repair process, 
sketch the cells and signaling factors involved in, and 
focus on the functional design and modification of scaf-
folds for ideal tissue-engineered constructs.
Osteochondral tissue and repair
The osteochondral interfacial tissue extended from the 
superficial cartilage to the underlying subchondral bone is 
composed of stratified zones. Figure 1 illustrates the struc-
tural hierarchy of osteochondral tissues. Each zone of inter-
facial tissue is divided into four distinct cartilage zones (i.e. 
superficial, middle, deep, and calcified cartilage), and the 
subchondral zone has different components defined by a 
unique composition and organization of cells and extracel-
lular matrix (ECM). The superficial articular cartilage, 
referring to the hyaline cartilage, is the smooth, shock-
absorbent tissue that forms a layer of approximately 3–4 mm 
thick on the articular surface. The articular cartilage repre-
sents approximately 60–80 wt% of fluids, and the remainder 
is composed of type II collagen and glycosaminoglycans 
(GAGs).8 The first of cartilage zones is the superficial or 
tangential zone occupying the upper 10%–20% of the artic-
ular cartilage, and has a small amount of proteoglycans and 
low permeability.9 Specialized proteins that facilitate the 
frictional characteristics of the tissue are secreted by the 
cells that reside in the superficial zone.10 The next middle 
zone occupying the following 40%–60% down is rich in 
proteoglycans but has a low number of cells. In addition, the 
arch-shaped middle zone has oriented collagen fibers, and is 
highly compressive, allowing recovery from articular sur-
face impacts.11 The deep zone has oriented collagen fibrils 
and cells perpendicular to the surface of the articular carti-
lage, and the fibrils are anchored on to the subchondral 
bone.9 The deep zone is also highly compressive as with the 
middle zone, but has fewer proteoglycans and the least 
cells.12 The osteochondral interface is structurally connected 
between a hyaline cartilage layer and an underlying bone 
plate,13 and plays a critical role in maintaining the cartilage 
integration. The osteochondral interface contains hyper-
trophic chondrocytes embedded in a mineralized cartilage 
matrix.14 Subchondral bone tissue comprises water, type I 
collagen, and hydroxyapatite (HA) crystals.
These different yet stratified distributions of physical 
and chemical traits account for the unique mechanical and 
biological functions of the osteochondral complex tissues. 
In fact, the osteochondral repair process relies on progeni-
tor cells or stem cells from the bone marrow to regenerate 
cartilage and bone tissue by allowing cell recruitment into 
the defect region.15 While an osteochondral injury that 
crosses vascular subchondral bones is spontaneously 
repaired by cell invasion into the lesion, the full-thickness 
defect repair of the osteochondral interface is transient 
because the articular cartilage contains few blood vessels 
and chondrocytes. According to the injury depth, osteo-
chondral lesions are classified into partial-thickness defect, 
full-thickness defect, and osteochondral defect. Owing to 
their poor self-repair capacity, most severe osteochondral 
lesions lead to the insurgence of severe pain, joint deform-
ity, and lack of joint motion.
Therefore, appropriate surgical treatments and techno-
logical developments such as grafting and tissue engineer-
ing are in high demand. Currently, common approaches for 
the treatment of osteochondral injury mostly rely on surgi-
cal techniques, as summarized in Table 1. As an invasive 
technique, patellar resurfacing currently used in total knee 
replacements showed anterior knee pain and cartilage 
wear.26 Similarly, microfracture or subchondral drilling 
stimulates the underlying bone marrow while contacting 
with the injured zone, and forms clots and fibrocartilage 
that contains a high quantity of type I collagen.27 These 
invasive techniques cause severe donor site morbidity and 
the pain thereby returns. In order to circumvent these 
shortcomings, transplantation of artificial or natural tissue 
grafts was introduced into osteochondral injured sites.28 
Osteochondral tissue grafts used in mosaicplasty have 
been used to treat large osteochondral injured sites. One 
study showed that the mosaicplasty efficiency increased 
with the use of hybrid fixation such as metal screws.29 
Several clinical and animal studies have shown that, while 
the mid-term outcome of mosaicplasty was acceptable, 
reliability in the long-term outcome is still questionable.30
Alternatively, cell-based treatments of osteochondral 
injury have emerged to overcome the aforementioned lim-
itations. For example, autologous chondrocyte implanta-
tion (ACI) and matrix-induced ACI (MACI) are routinely 
used for cartilage repair in clinical applications. While 
ACI is a quick and simple surgery with a high success rate, 
it is limited by instability or loss of chondrocytes under in 
vitro culture. In fact, autologous chondrocytes have often 
been shown to lose cartilaginous phenotype during the in 
Figure 1. Cross section of osteochondral tissue.
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vitro cell expansion after their isolation from cartilage tis-
sue,31 even though the sufficient number of cells is obtained 
from the individual harvested site. To address this chal-
lenge, an extra step of cartilage tissue fragmentation was 
introduced to the existing ACI method. Their results 
showed stable cell migration and growth, and indicated 
that fragmented cartilage tissue acted as a scaffold equal to 
a native ECM for chondrocyte redistribution.32 MACI is a 
next generation product that can also overcome the limita-
tion of ACI, and has the potential to become an established 
method. The matrix used for the chondrocytes was type I/
III collagen scaffold and fibrin glue was introduced to 
secure the lesion. Clinical results have been revealed on a 
large and deep osteochondral implantation via minimally 
invasive methods without noticeable graft-related inflam-
mation.33 However, these techniques often resulted in 
donor site morbidity over long periods after treatment.34 
Therefore, tissue-engineering approaches are in demand as 
a promising technological advance for osteochondral 
repair without risks that induce donor site morbidity, host 
immune responses, and disease transmission.
As the key components comprising tissue engineering, 
cells, signaling molecules, and scaffolds have shown great 
advances in terms of their basic knowledge and their bio-
logical interactions with each other. We briefly overview 
the cell sources and signaling molecules in the following 
section, and then focus further on the scaffolds with their 
recent technological developments and on the combinato-
rial designs with cells and signaling molecules; this is con-
sidered to be a promising approach to engineering 
functional tissues and mimicking tissue-equivalents.
Cell sources for osteochondral repair
Cells migrate into defect areas and play an important 
role in repair processes by secreting ECM proteins, 
Table 1. Current surgical techniques for osteochondral repair.
Surgical procedure Invasive 
degree
Features Reference
Mosaic-type osteochondral 
autologous transplantation 
(OAT) and microfracture (MF)
HIGH Patient clinical improvement in OTA and MF
Superior articular cartilage repair in OTA to MF
Gudas et al.16 
MF-combined osteochondral 
paste
MODERATE Poor Safranin-O and type II collagen staining in 
MF group
High GAG content and the DNA-normalized 
GAG
High expression of type II collagen and aggrecan
Xing et al.17
MF with hole geometry HIGH No significant effect in osteochondral repair Kok et al.18
Mix-mosaicplasty VERY  
HIGH
Fibrocartilage-like tissue
Small chondrocyte-like cells
Full-thickness defect regeneration
Leng et al.19
Mosaicplasty grafting MODERATE Improved mean pain score
Alternative to MF
Repair deterioration from 12 months post-
operation
Solheim et al.20
ACI HIGH Hypertrophy of transplant
Insufficient regenerative cartilage and 
delamination
Niemeyer et al.21 
MODERATE Effective in younger patients
Suitable for meniscus injuries
Cruciate ligament and malalignment of cartilage
Ossendorf et al.22
MACI MODERATE Limited effective over 24 months Basad et al.
23
 Alternative to MF
Arthroscopic autogeneous 
osteochondral mosaicplasty
HIGH Multiple surgery procedure Hangody et al.24
Fibrocartilage formation near donor site  
Total joint replacement VERY HIGH Metal toxicity and sensitivity
Bone necrosis and changes in vascular supply
Evans et al.25 
ACI: autologous chondrocyte implantation; MACI: matrix-induced autologous chondrocyte implantation; GAG: glycosaminoglycan.
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resulting in new tissue formation. However, full-thick-
ness defects require surgical procedures and tissue 
grafts. Along with scaffolds, the source of cells benefi-
cial to osteochondral tissue can provide a potential for 
osteochondral repair. Therefore, the selection of an ideal 
cell source for osteochondral repair is significantly 
important to improve repair efficiencies. A desired cell 
source must have no limitations in the amounts available 
and be easy to maintain in vitro in terms of cell manipu-
lation. In addition, cells without risks such as host 
immune responses and disease transmission must be 
used in tissue engineering. As listed in Table 2, two com-
mon cell resources, including stem cells and tissue-spe-
cific cells, are currently used for osteochondral tissue 
engineering. Various stem cells have recently gained 
considerable attention and are an attractive resource to 
meet the criteria mentioned above. Of such stem cells, 
adult mesenchymal stem cells (MSCs) are the most 
widely studied in the field of osteochondral tissue engi-
neering and could be appropriate due to their availability 
and high capacity for proliferation and differentiation. 
Despite their promise, undifferentiated cells have often 
shown limited/unsatisfactory capacity for osteochondral 
repair due to the multi-potency and difficulty in cellular 
fate control. Thus, pre-differentiated cell lineages have 
been used. Along with MSCs, pluripotent stem cells 
(PSCs), particularly those induced from adult/patient 
cells, that is, induced PSCs (iPSCs), have also been con-
sidered as a potential therapeutic cellular tool for carti-
lage regeneration although they are still in emerging 
state for clinical availability and relatively less 
documented. Ko et al.41 have recently reported the 
implantation of chondrocyte-based human iPSCs into 
cartilage defects with improved cartilage repair capacity. 
However, more studies on iPSCs for osteochondral 
repair are considered to follow in the near future. 
Meanwhile, tissue-specific cells, such as osteoblasts and 
chondrocytes, have also been introduced as promising 
cell resources for bone and cartilage tissue regeneration 
in osteochondral repair, respectively. Nonetheless, with-
out the use of proper osteochondral inductive factors, the 
synthesis of ECMs representing each specific tissue has 
been difficult to achieve, and requires appropriate extra 
therapeutic systems.
Osteochondral scaffolds and 
functional designs
Scaffolds are a fundamental factor in cell-based tissue engi-
neering. For the success of osteochondral tissue engineer-
ing, the primary requirements of scaffolding materials 
include biocompatibility, biodegradability, mechanical sta-
bility, and pore structure. Furthermore, the types of scaf-
folds, such as hydrogel, porous foam, and fibrous network, 
determine the physical and biological properties of the 
scaffold itself as well as the way how cells and signaling 
molecules are utilized. Scaffolds enable cells to adhere, 
migrate, grow, and differentiate into chondrogenesis and 
osteogenesis, consequently helping the formation of new 
osteochondral tissue. The following section discusses the 
considerations required for the successful fabrication of 
osteochondral scaffolds.
Table 2. Cell resources currently used in osteochondral tissue engineering.
Cell resource Cell type Features Reference
Stem cells
 
Umbilical cord 
MSCs
Facilitate scaffold and tissue integration. Wang et al.35
Amniotic fluid–
derived stem  
cells
Differentiation into osteoblasts and chondrocytes encapsulated 
in 2% of alginate
Non-requirement for osteochondral medium and production 
of protein-rich ECM
Rodrigues et al.36
 
Synovium-derived 
MSCs
Characteristics of MSCs with an ability to differentiate into 
osteoblasts and chondrocytes.
Integration into the surrounding cartilage
Koga et al.37 
Bone marrow-
derived MSCs
Development toward both chondro- or osteo-lineages without 
fibrous tissue formation
Complete tissue integration and low host immune response
Betsch et al.38 
Tissue-
specific cells  
Chondrocytes Complete mechanical stability
High tissue integration into the surrounding tissue
Horas et al.39
 
Clinically and histologically stable  
Osteoblasts High SPP1 mRNA expression Innes et al.40
 Up-regulation of RUNX2  
MSCs: mesenchymal stem cells; ECM: extracellular matrix; RUNX2: Runt-related transcription factor 2.
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Choice of biocompatible and degradable 
materials
It is well known that scaffolds must be fabricated from bio-
compatible materials which do not elicit immune responses 
or foreign body reactions. In addition, the biodegradation 
of scaffolds during in vivo treatment should closely match 
tissue growth rates. The selection of proper materials to 
meet these requirements is thus the first consideration, and 
the compositions currently used for osteochondral scaf-
folds range from natural and synthetic polymers, metallic 
materials, or inorganic materials, to their composites.
Natural or synthetic polymers have excellent flexibility 
to adapt their shape to wanted forms via various molding 
and casting techniques. Beneficial molecules for cells are 
rich in natural biopolymers, such as GAGs, collagen, and 
GAG-like polysaccharides, and thus, these natural biopol-
ymers have been easily introduced into synthetic biopoly-
mers, resulting in improving the biological affinity of the 
scaffold to the host tissue. For example, gelatin-conjugated 
calcium-alginate scaffolds have improved cell adhesion 
and proliferation, and showed differentiation of MSCs into 
chondrogenic and osteogenic cell lineages.42 While the 
cell compatibility and bioactivity of natural polymers are 
generally superior to those of synthetic polymer, they have 
relatively weak mechanical properties and the degradation 
rate of them is not easy to control. 
On the other hand, biodegradable synthetic polymers, 
including aliphatic polyesters have been applied to osteo-
chondral scaffolds with a broad spectrum of chemistries 
and processes to control their intrinsic characteristics such 
as the degradation rates. Depending on the synthesis con-
ditions the mechanical properties can also be easily tuna-
ble. However, the poor surface activity and cell affinity 
have generally been the weakness of the synthetic poly-
mers. To improve this, blending or copolymerization 
approach between different polymers has been made. For 
example, polyvinyl alcohol (PVA) was introduced into 
polycaprolactone (PCL) nanofibrous scaffolds to improve 
the biocompatibility and tensile properties of the scaffold. 
As a consequence, enhanced proliferation and chondro-
genic differentiation of MSCs were shown in comparison 
with pure PCL scaffolds.43
However, typical polymeric scaffolds are still insuffi-
cient to sustain mechanical stress originating from the joint 
movement or biodegradation and further from the sub-
chondral bone region. Therefore, these polymeric scaf-
folds have been hybridized with inorganic materials to 
improve their mechanical properties. Examples include 
metals and ceramics such as bioactive glasses that can par-
ticipate in the bone part of the osteochondral scaffold. As a 
bone part, a small content of metallic materials such as 
titanium, stainless steels, cobalt, and their alloys helped to 
improve the capability of sustaining mechanical loads and 
ability to bond to weaker or softer scaffold materials for 
the cartilage area. For example, a biphasic construct, tita-
nium-bound polyethylene glycol (PEG) hydrogel, was 
produced for cartilage and bone growth and integration in 
adjacent tissues.44 However, these metallic materials in tis-
sue engineering show a lack of biodegradation over time 
and may cause tissue abrasion or corrosion.45 Thus, care 
must be taken when metallic materials are used for osteo-
chondral scaffold design.
Bioactive ceramics such as calcium phosphates or bio-
active glass are known to be biocompatible and even bio-
degradable, and have been primarily used as the bone part 
of osteochondral scaffolds. Particularly, their role in 
improving biomineralization is a promising aspect for 
bone formation. However, owing to their stiff nature pos-
sibly leading to brittleness, composites with biodegradable 
polymers have been popularly approached. For example, 
the stratified scaffold composed of agarose hydrogel and a 
composite polylactide-co-glycolide (PLGA)/bioactive 
glass improved mineralization by virtue of bioactive glass 
and resulted in integrative osteochondral repair.46 
Accordingly, while the bioactive ceramics themselves are 
brittle, they can provide a favorable stiffness level for bone 
formation when incorporated within a polymeric phase.
Consideration of mechanical properties
Further understanding of mechanical properties of osteo-
chondral tissue can contribute to the effective design of 
osteochondral scaffolds. Osteochondral interfacial tissue 
has different mechanical strengths depending on the prop-
erty at each stratified layer. Mismatched viscoelastic 
properties of osteochondral tissue lead to stress disparities 
between cartilage tissues. Superficial cartilage can with-
stand a local compressive stress of 0.08– 2 MPa, tensile 
modulus of 5–25 MPa, and equilibrium shear modulus of 
0.05–0.25 MPa.47 These differences arise from the bio-
logical and chemical composition and thereby from 
mechanical strengths in each zone. In order to optimize 
resistance in osteochondral tissue, superficial collagen 
exists parallel to the shear direction, while collagen in the 
deep zone is perpendicular to the surface. Owing to this 
highly organized structure and its properties, artificial rec-
reation of this tissue is still challenging. Intensive pro-
gress on remodeling cartilage has been made using 
transforming growth factor-β1 (TGF-β1) and mechanical 
stimulation to improve its tensile modulus up to more than 
3.4 MPa,48,49 which, however is, much lower than the 
native tissue tensile values mentioned above. Recent stud-
ies emphasized the mechanical properties of osteochon-
dral tissue by arraying and cross-linking collagen 
organization.
Furthermore, osteochondral tissue operates as a fric-
tionless bearing while transferring loads to the bone to pre-
vent local stress. Although the phenomena of the onset of 
osteochondral degeneration and its progress have already 
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been studied extensively, the exact mechanisms on the 
mechanical environments of osteochondral tissue are yet 
to be elucidated. This is an essential issue in the fabrication 
of scaffolds with a low-friction surface that could integrate 
with surrounding tissue and maintain the mechanical sta-
bilities of the implant. The lubricated property of cartilage 
arises from the complex combination of squeeze film 
lubrication, elasto-hydrodynamic lubrication, boundary 
lubrication, interstitial fluid pressurization, and a migrat-
ing contact area.47 Without the friction (coefficient ~0.005) 
property of the cartilage, contact shear would result in 
considerable abrasion.50 Shi and Xiong51 developed low- 
friction cartilage scaffolds (coefficient values ~0.05) com-
posed of PVA/polyvinyl pyrrolidone (PVP) hydrogels that 
have biocompatibility and excellent weight-bearing prop-
erties. Despite progressive challenges, osteochondral scaf-
folds that meet mechanical properties of the native cartilage 
tissue mentioned have not yet been reported.
Design of pore structure
In most scaffolds, the pore structures affect the cell 
responses and their further organization in the tissue, regu-
lating cell invasion, vascularization, and tissue regenera-
tion. While the hydrogel type characterizes water-filled 
channels and polymer networks, the space-open channels 
are the general feature of scaffolds. The porous structure 
relies primarily on the fabrication process. Conventional 
methods for these pore-structured scaffolds include fiber 
bonding, solvent casting/particulate leaching, gas foam-
ing, and phase separation.52 The porous scaffolds pro-
cessed using these techniques have controlled pore size 
and porosity suitable for tissue engineering. For example, 
the interconnected pore structure can meet the demand of 
the cell behaviors on the scaffold. Particularly, the region 
participating in the bone part of the osteochondral scaf-
folds should mimic bone morphology, structure, and func-
tion to optimize integration into the adjacent tissue. Native 
bone creates a porous environment with 50%–90% poros-
ity,53 and its pore sizes are typically measured in the order 
of 1 mm in diameter.54 In practice, however, in several 
studies on the effects of pore size, the scaffold structure 
composed of porosity higher than 50% and pores larger 
than 300 µm is recommended to achieve direct osteogen-
esis with enhanced vascularization.55 On the contrary, 
small pores for the scaffold have been suggested for 
favorable chondrogenesis on 90–120 µm pores, where 
MSCs proliferate and form cartilage tissue on the 
scaffold.56
Fibrous scaffolds, particularly with nanofibrous mor-
phology, have recently shown considerable promise for the 
repair of tissues, such as osteochondral tissue. This 
nanofiber morphology can be easily achieved by an elec-
trospinning technique.57 A polymer solution is ejected 
through a needle into fibers under a strong electric field. 
The nanofibrous network facilitates cell adhesion and 
guides growth and tissue-specific differentiation.58 In 
addition, nanofibrous scaffolds can be easily modified by 
virtue of a tunable process, which enables gradient compo-
sition and tuning of fiber and pore geometry. When the 
nanofiber structure was combined with a microfiber scaf-
fold, the cell seeding efficiency and 3D networking were 
improved. MSC differentiation was enhanced more on the 
microfibrous large-pored scaffold than that achieved on 
the nanofibrous micro-pored scaffold.59 Furthermore, an 
example of alternating bilayers composed of PCL micro-
fibers and PCL nanofibers showed the promotion of osteo-
genesis and osteochondral ossification, respectively.60 
Here, excellent MSC attachment was shown on nanofib-
ers, but cell infiltration through nanofibers was still lim-
ited. However, these studies were performed in very small 
pore sizes of less than 30 µm, and thus were not appropri-
ate for evaluating osteochondral tissue regeneration in 
terms of the pore size. A number of studies have been car-
ried out on the optimal pore structures of electrospun oste-
ochondral scaffolds by utilizing the inherent advantages of 
fiber types. Zhang et al.61 reported the advantageous effect 
of a biphasic scaffold composed of collagen and electro-
spun polylactic acid (PLA) nanofibers with pore sizes of 
50 ~ 300 µm. Despite the prominent progress, the conven-
tional electrospun fibrous scaffold with pores smaller than 
300 µm may still hamper osteogenesis. Therefore, specific 
processing to make pores larger than the 300 µm of fibrous 
biphasic scaffolds is required for osteogenesis in osteo-
chondral repair. For example, in order to produce a larger 
pore size, laser processing with femtosecond pulses was 
attempted and resulted in improvement of the pore size by 
up to 500 µm.62 In another case of electrospun fibrous scaf-
folds, a combination with a salt leaching method showed 
an approach that can increase pores, but resulted in reduced 
mechanical stability.57
Recently, attention has been paid to the rapid prototyp-
ing (RP) technique to produce optimal osteochondral 
scaffolds with highly accurate control over pore geometry 
by a computer-aided design/computer-aided manufactur-
ing system and a layer-by-layer process. Unlike the con-
ventional approaches previously described, this technique 
enables easy fabrication into well-defined 3D intercon-
nected pore structures while possessing appropriate 
mechanical and biochemical properties.63 Hutmacher64 
developed a fused deposition modeling (FDM) technique 
to fabricate highly porous PCL scaffolds for bone tissue 
engineering. This technique based on computer-guided 
3D plotting is used to supply a pre-formed fiber through a 
heated nozzle and rollers. The scaffold fabricated by FDM 
has a narrow processing window and complex geometries, 
and the use of a pressurized syringe instead of a heated 
nozzle has made it possible to achieve a wide processing 
capability independently of the molten polymer tempera-
ture. As a modified FDM technique, a 3D fiber deposition 
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(3DF) technique developed by Woodfield et al.65 was 
reported to fabricate highly porous osteochondral scaf-
folds with interconnected pore channels and an average 
pore size (415 µm). The 3DF fabrication is processed by 
molten polymer deposition from a motor-driven syringe 
on a stationary stage under a constant pressure.66 It was 
reported that the average interconnecting pore sizes of the 
scaffold fabricated by a 3DF technique can be increased 
by up to 1650 µm.67 It is assumed that a scaffold with this 
pore structure is suitable for the application of osteochon-
dral tissue engineering. Furthermore, Bian et al.68 devel-
oped a combined technique of lithography and gel-casting 
to fabricate biphasic scaffolds comprised of β-tricalcium 
phosphate and type I collagen. The pore size and porosity 
in the bone phase of the ceramic biphasic scaffolds were 
700–900 µm and 50%–65%, respectively. Moreover, a 
strong physical interlock between the cartilage phase and 
bone phase produced an appropriate binding force to rec-
reate a biomimetic transitional structure.
Hydrogel scaffolds
Hydrogels comprise hydrophilic polymeric networks filled 
with a large amount of water. Owing to the ability of water 
uptake and swelling, hydrogels have been considered as 
the 3D matrices that mimic the 3D gel-like native ECMs, 
including cartilage. Therefore, for the culture of cells and 
tissue engineering, hydrogels have been widely employed 
as scaffolding materials. As with other scaffolds, hydrogel 
scaffolds should also support structural integrity as well as 
mechanical robustness to enable appropriate tissue forma-
tion.69 In addition, the hydrogel has the ability to safely 
incorporate drugs and growth factors and then deliver 
them in a controlled manner. For these reasons, viscoelas-
tic hydrogels, such as type I collagen, gelatin, or GAG 
components, have been used for the repair of irregular car-
tilage lesions. However, these hydrogels, composed of a 
single phase, are definitely inadequate to define complex 
structures of interface tissue and to sustain osteochondral 
interface tissue with a wide range of motion because their 
mechanical stability is too weak.70 Furthermore, although 
these hydrogels somewhat enable the flexibility of cell 
migration and transfer of nutrients and oxygen to the cells, 
it is evident that cell behaviors and responses guided by 
these physicochemical properties and a single composition 
are vastly inferior to those shown in the typical porous 
scaffolds. As a result, cell penetration into each phase and 
finally cell distribution are restricted within the viscoelas-
tic hydrogels.
Therefore, interest in hydrogel-based biphasic scaffolds 
to define osteochondral tissue properties has been increas-
ing. Moreover, viscoelastic hydrogels have been used for 
the controlled release of growth factors that are beneficial 
for osteochondral repair by forming delivery vehicles such 
as microspheres. For example, biphasic composite 
hydrogels comprising PEG and gelatin microspheres to 
load growth factors were fabricated via a two-step cross-
linking procedure.71 Here, gelatin microspheres in the 
biphasic scaffolds served as enzymatically digestible poro-
gen as well as a delivery vehicle. While excellent release 
kinetics of growth factors in the scaffold were shown in 
vitro and in vivo, the mechanical stability of the scaffold 
with the pore structure attributed to the microspheres used 
as a porogen was still not satisfactory for osteochondral tis-
sues. Hybridization of inorganic components with hydro-
gel-based biphasic scaffolds can alleviate the issue of their 
mechanical stability. Moreover, the gradient inorganic 
component of a hybrid biphasic scaffold is thought to 
induce an osteochondral-like transition in the ECM synthe-
sis and cell phenotype. Munoz-Pinto et al.72 reported the 
fabrication of PEG hydrogels cross-linked to gradient poly-
dimethylsiloxane using a photolithographic technique. As a 
result, the mechanical properties of the scaffold were 
enhanced and transdifferentiation of osteoblasts into chon-
drocyte-like cells was observed with increasing scaffold 
inorganic content, as indicated by the increased synthesis of 
ECMs such as chondroitin sulfate and type II collagen and 
by the upregulated sox9, a chondrocyte differentiation-
associated transcription factor. Although a number of 
attempts to fabricate hydrogel-based biphasic scaffolds 
were evaluated as “promising,” the interfacial stabilities 
between the two phases are still questionable due to the fee-
ble shear forces of hydrogels.
Biphasic structure and interfacial integration
Conventional monophasic scaffolds were inadequate to 
replace defective interfacial cartilage-to-bone tissue that 
possesses anistropic structural properties and functions. A 
variety of multiphasic scaffolds for the osteochondral 
interface have thus been suggested. Multiphasic scaffolds 
should provide an optimal environment to direct the com-
munications of cell/cell and cell/matrix. Also, the inte-
grated materials can transfer physical or chemical events 
from the cartilage to the bone layers, because the interface 
tissue is exposed to shear forces over a large range of 
motion.
Cell interaction with the scaffold makes possible the 
interfacial integration between the cartilage and bone phases 
of the osteochondral scaffold; in fact, cell-laden scaffolds 
with a gradient of phases showed a greater osteochondral 
tissue formation after implantation than the acellular scaf-
folds.73 Therefore, homogeneous or heterogeneous cell 
composites with osteochondral scaffolds with gradient 
phases have been developed to improve mechanical and 
functional integrity. Yunos et al.74 reported interface-inte-
grated biphasic scaffolds, composed of PLA fibers as a car-
tilage phase and PLA-coated bioactive glass scaffold as a 
bone phase, by distributing homogeneous single cells within 
the two phases. Similarly, heterogeneous cell-laden biphasic 
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scaffolds composed of chondrocyte-laden agarose hydrogel 
and osteoblast-laden microsphere composites with bioac-
tive glasses have also been developed.46 Here, the interac-
tion of cells contained in the biphasic scaffold avoided 
delamination of each layer, and improved mechanical stabil-
ity. In another case, the dynamic culture of MSCs on bipha-
sic scaffolds incubated in bioreactors improved the 
mechanical properties of the scaffold due to the shear stress 
generated in the bioreactor.75 Moreover, the enhanced cell 
viability on or in the scaffold cultured in the bioreactor 
resulted in tissue growth in vivo due to the supply of a 
homogeneous medium solution and shear stress.76 Figure 2 
illustrates how the cells laden onto the biphasic scaffolds 
contribute to improving mechanical functions and interface 
integration.
Scaffolds delivering signaling molecules
Interest in signaling molecules and their consequences in 
the field of tissue engineering has grown with delivery 
strategies from the scaffold, affecting tissue repair effi-
ciency. Examples of signaling molecules include growth 
factors and therapeutic drugs or genes. Likewise, osteo-
chondral tissue engineering has utilized these strategies to 
facilitate cell growth and tissue formation. These strategies 
have facilitated smart biphasic scaffolds in osteochondral 
tissue engineering. The inductive conditions using signal-
ing molecules influence cells on the ECM formation of 
osteochondral tissue, and cells may continuously secrete 
ECM proteins to ensure a comfortable scaffold environ-
ment while residing on the scaffolds. However, there is a 
subsequent challenge to manage spatiotemporal control of 
specific signaling molecules within the stratified scaffold. 
Therefore, along with scaffold design, effective carriers are 
needed to efficiently synthesize the osteochondral ECM. 
These considerations must be accompanied by comprehen-
sive knowledge on the unique property of each matrix and 
of the physicochemical relationship between the carriers 
and molecules in terms of the efficiency of loading and 
release. This section explores the recent designs of the elab-
orate delivery techniques of osteochondral biphasic scaf-
folds, where critical factors such as spatiotemporal release 
and dose control are strongly considered. Table 3 
summarizes the scaffolding system for osteochondral repair 
with a delivery potential of therapeutic molecules, such as 
growth factors, drugs, and genes.
In terms of the signaling molecules for osteochondral 
repair, the currently available growth factors are listed in 
Table 4. Moreover, chemical drugs or genes have been 
intensively explored for additive or synergetic effects of 
osteochondral repair. Here, we briefly summarize the oste-
ochondral effects of various growth factors. Among these, 
fibroblast growth factors (FGFs) or TGF-β family enhance 
cartilage ECM formation under the culture condition of 
chondrogenic cells, while bone morphogenetic proteins 
(BMPs) induce osteogenesis of cells. Therefore, the use of 
these growth factors provides osteochondral inductive 
effects. The construction of osteochondral tissue-like scaf-
folds has been attempted in various studies using this strat-
egy prior to implantation. MSC-seeded fibrin hydrogel/
collagen-type I/III biphasic scaffold incorporating TGF-β 
improved cartilage ECM synthesis, owing to sustained 
release of TGF-β up to 7 days, which aided in inducing 
MSCs’ chondrogenesis.96 While the use of growth factors 
shows effects on osteochondral repair, gaining more sus-
tainable and controllable release is a key issue, which can 
be facilitated by the fine design of scaffolds.
One promising approach is to encapsulate signaling 
molecules such as therapeutic growth factors or drugs in 
microspheres, which are then incorporated into biphasic 
scaffolds. Therapeutic molecules can be either surface-
tethered to or incorporated within the microspheres. For 
the former case, the surface chemistry required to link 
molecules and drugs should be properly controlled.97 
Meanwhile, for the latter case, the drug molecules can be 
incorporated during the microsphere preparation, and thus, 
a larger number of drug molecules can be loaded. The use 
of microspheres is versatile because they can be utilized as 
a scaffold as well as a delivery vehicle. This is particularly 
a good model for the repair of osteochondral tissue that 
requires a variety of signaling molecules. A spatiotemporal 
delivery strategy for osteochondral tissue engineering is 
depicted in Figure 3. For example, precise control over the 
spatiotemporal release kinetics of multiple growth factors 
is able to participate in damaged tissue healing.98 The 
sequential growth factor delivery system was designed to 
produce different profiles of growth factor release from the 
bilayered matrices with different physicochemical proper-
ties.100 Analogously, two types of microspheres with dif-
ferent degradation rates have been suggested to deliver 
two functional growth factors after the incorporation of the 
microspheres into a scaffold.99 These systems enable 
sequential and tighter control of release profiles. In prac-
tice, Wang et al.93 introduced a two-carrier system into 
porous polymer scaffolds to load different combinations of 
BMP-2 for osteogenesis and insulin-like growth factor I 
(IGF-I) for chondrogenesis with spatial distribution and 
temporally controlled release. Both growth factors were 
Figure 2. Schematic illustration of cell–cell contact and 
cell–matrix contact in the cell-laden biphasic scaffold resulting 
from the strategy used to stabilize the mechanical property and 
to integrate the interfaces of each phase.
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loaded onto PLGA/silk microspheres that have the ability 
to sustain the release of BMP-2 but are inefficient in the 
release of IGF-I due to the low loading efficiency. Although 
PLGA/silk microspheres showed inefficient MSC chon-
drogenesis, it is significant that this system offered a new 
option for the co-delivery of growth factors by spatiotem-
poral control.
In case of gene delivery techniques for osteochondral 
repair, non-viral cationic polymers or liposomes have 
been intensively used as carriers to promote gene trans-
fection efficiency. For example, lipid-based endogenous 
gene delivery of FGF-2 and/or IGF-I101 was achieved to 
culture gene-modified chondrocytes on osteochondral 
scaffolds. It was reported that IGF-I stimulated the pro-
liferation of chondrocytes102 and their synthesis of type 
II collagen103 and proteoglycan.104 Madry et al.105 
reported that IGF-I expressing chondrocytes led to 
enhanced cartilage repair in vivo in osteochondral defect 
model. Recently, gene delivery system has been 
advanced to immobilize the carriers onto scaffolding 
matrices to effectively control cellular differentiation by 
specific target genes. For example, Chen et al.106 reported 
that the gene-activated matrix-based delivery of two 
plasmids encoding TGF-β1 and BMP-2 in MSCs immo-
bilized into the biphasic scaffold was conducted to dif-
ferentiate chondrogenesis and osteogenesis, respectively. 
Excellent MSC differentiation into chondrocytes and 
osteoblasts was shown in the biphasic scaffold com-
posed of chitosan-gelatin layer for cartilage and HA for 
bone. The authors suggested that multi-tissue regenera-
tion was performed in the biphasic scaffold by the 
gene delivery system. Although the study explored the 
gene delivery system for the osteochondral tissue repair, 
the delivery efficiency in the system is still not satisfac-
tory because delivery of naked genes without any carri-
ers is known to show a low efficiency. Theoretically, the 
spatiotemporal delivery of specific genes from the 
biphasic scaffold may direct cellular differentiation, 
facilitating the osteochondral regeneration. However, 
successful studies on the basis of this ideal strategy have 
not yet been reported. Instead of using the non-viral gene 
carriers, recombinant baculoviruses expressing BMP-2 
were seeded into the osteochondral scaffolds containing 
de-differentiated chondrocytes, and then cultured in a 
rotating bioreactor for up to 3 weeks, which conse-
quently led to the regeneration of hyaline cartilages.77
Table 3. Growth factors currently used in osteochondral tissue engineering.
Signaling molecule Carrier Observations Reference
Gene
 
 
BMP-2 Porous PLGA Increased GAG content in treated groups Chen et al.77
Low level of type I collagen and increased 
type II collagen shown in the treated group
 
Collagen sponge 
reinforced by PEG
Increased ALP activity in test groups
Stable complex formation with plasmid 
DNA through electrostatic interaction 
while showing increased stability
Hosseinkhani 
et al.78 
VEGF/BMP-2 Hollow cylindrical 
PLGA scaffold
Regeneration proximal and distal ends of 
the bony defects by co-expression
Lin et al.79
hIGF-I gene–
modified BMSCs
1.2 wt/% calcium-
alginate solution
hIGF-I gene effective expression with high 
subchondral bone and cartilage integration
High ECM production and distribution
Leng et al.80 
Growth 
factor 
 
TGFβ-1/BMP-2 PLGA 
microspheres, 
dispersed in an 
alginate matrix
High gene expression in the treated groups
High quality of cartilage and tissue 
integration
Reyes et al.81
 
TGF-β3/IGF-I Gelatin 
microspheres 
in oligo-PEG 
fumarate hydrogel
Excellent formation of subchondral bone 
and GAG
Negligible effects of TGF-β3 in cartilage 
morphology and histological scoring
Yi et al.82 
BMP-2 Hyaluronic 
hydrogel system
Healing with fibrocartilage-like tissue 
formation.
Severe ectopic bone formation observed in 
test group affecting joint functionality
Aulin et al.83
 
BMP: bone morphogenetic protein; GAG: glycosaminoglycan; ALP: alkaline phosphatase; PLGA: polylactide-co-glycolide; VEGF: vascular endothelial 
growth factor; PEG: polyethylene glycol; BMSCs: bone marrow mesenchymal stem cells; ECM: extracellular matrix; hIGF-I: human insulin-like growth 
factor I; TGF: transforming growth factor.
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Perspective and concluding remarks
We reviewed the recent update of considerations required 
in osteochondral tissue engineering by discussing the pre-
viously published studies. Considering that interfacial tis-
sue has a stratified structure depending on the unique 
property, theoretically, osteochondral scaffolds need to 
have multiphase structures to mimic the structure of the 
native stratified tissue. However, the multiphasic struc-
tures are too complex to control the properties of each 
phase, for example, degradation rates of each phase and 
shear forces between the phases. Therefore, the biphasic 
scaffold divided into a cartilage phase and a bone phase, 
which is simpler than the multiphasic scaffold, could be 
one of the most optimal osteochondral scaffolds to define 
interfacial tissue. Nonetheless, the mechanical stability 
between the two phases of the biphasic scaffold is still 
questionable. This weak stability could be because the 
integration of these two phases has been performed by 
physically combining the two phases after the individual 
fabrication of each phase. Although few studies have been 
reported that circumvent this limitation by using cell-sub-
stratum contact, the shear force between the two phases of 
the biphasic scaffold would still become weaker during its 
Table 4. Potential delivery of therapeutic molecules including growth factors, drugs, or genes from the scaffold for osteochondral 
repair.
Growth factor Osteochondral effects Reference
TGF-β1 Synchronized development of cartilage and subchondral bone.
Earlier modulator for cartilage repair before BMP-2 action with hyaline-like 
cartilage formation.
Scherer et al.84 and Reyes 
et al.85
FGF-2 Hyaline-like cartilage and subchondral bone.
Increased stiffness of the osteochondral construct.
Maehara et al.86 and 
Nakayama et al.87
BMP-2 High-quality cartilage and tissue integration.
In vivo BMP-2 causes osteochondral differentiation of MSCs even with short 
exposure.
Combination of BMP-2 further enhanced osteochondral repair effects.
Noel et al.88, Sakata 
et al.89 and Jung et al.90
BMP-7 Formation of mineralized tissue and ectopic bone.
Combination of other growth factors enhanced chondrogenesis and osteogenesis.
Dormer et al.91 and 
Tiwary et al.92
IGF-I Superior growth morphology and surface architecture of the neotissue.
Hyaline cartilage formation.
Increased chondrocyte viability.
Single delivery of IGF-I showed higher subchondral bone morphology.
Wang et al.93, Teng 
et al.94 and Fransès et al.95
VEGF Critical factor for chondrocytes survival.
High osteochondral vascular density.
Sakata et al.89 and Fransès 
et al.95
BMP: bone morphogenetic protein; VEGF: vascular endothelial growth factor; PEG: polyethylene glycol; IGF-I: insulin-like growth factor I; TGF: 
transforming growth factor; FGF: fibroblast growth factor.
Figure 3. Spatiotemporal delivery from a biphasic scaffold containing therapeutic molecule–loaded microspheres with different 
degradation rates.98,99
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degradation after implantation in vivo. In order to over-
come this, a one-pot method is required to fabricate a 
biphasic scaffold that can resist the shear force between 
the two phases.
In addition, it is still doubtful whether adequate chon-
drogenesis and osteogenesis can be mediated on each 
phase of the biphasic scaffold. This is because the respec-
tive cells on each phase could function as unexpected 
modulators affected by the inadequate release of signaling 
molecules. In order to overcome this challenge, a spati-
otemporal targeting delivery system needs to be suggested. 
Using this system, the respective cells cultured on each 
phase would recognize the specific signaling molecules 
beneficial for the individual regeneration of each tissue. 
Therefore, we propose that future studies make full use of 
a spatiotemporal targeting delivery strategy in the biphasic 
scaffold that can withstand the shear force between the two 
phases.
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